project id: TCGA-BLCA; case submitter id: TCGA-FD-A62S; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.59; rna integrity number: 8.4; age at index: 60; days to birth: -22000; days to death: 406; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Dead; year of birth: 1953; age at diagnosis: 22000; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 368.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 49; days to sample procurement: 0; initial weight: 1150.0; portion submitter id: TCGA-FD-A62S-01A-11; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 2.0; percent necrosis: 0.0; percent neutrophil infiltration: 4.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;